• Home
• About Makaira
• Investment Team
• Partner Resources
• Portfolio Companies
• Submit Your Executive Summary
• Contact Us
• News
  • Cardiosolutions names Dr. Lars Svensson Chief Surgical Officer
  • Five Questions With: Dr. A. Robert Buonnano
  • Knees In Need
  • CE Mark approval for UniCAP knee
  • Spirus Medical Announces 510(k) Clearance from FDA for Expanded Use of Endo-Ease(R) Discovery SB(TM)
  • Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
  • STDMed Inc. Brings Forward Fourth Startup, Closes Series A Financing for Cardiosolutions
  • Spirus gets $8.5M Series B for med devices
  • Frost & Sullivan Names Spirus Medical 2007 U.S. Endoscopy Entrepreneurial Company of the Year
  • Spinoff cycle: STD Med builds devices, startups
  • Arthrosurface Raises $10.5 million in 4th Round of Preferred Equity Financing
  • STD Manufacturing Announces Sale Of AngioLink Corporation
  • Medtronic Acquires Angiolink Corporation, Maker Of Wound Closure Device For Vascular Procedures

STDMed Inc. Brings Forward Fourth Startup, Closes Series A Financing for Cardiosolutions

PRESS RELEASE
Ronald Murphy V.P. Investor Relations 781-828-4400
Andrea Patisteas V.P. Sales and Marketing 781-828-4400

IMMEDIATE RELEASE

Stoughton, MA - September 19, 2007: STDMed Inc. (www.stdmed.com) recently announced the closing of a $7 million dollar Series A Convertible Preferred Stock financing for its fourth incubated medical device company, Cardiosolutions Inc. Cardiosolutions Inc. has gathered Series A funding from BioVentures Investors, a leading Cambridge MA based life sciences venture capital firm along with a group of accredited investors.

Cardiosolutions, Inc. was founded to develop a less invasive, percutaneous alternative to open heart surgical repair of the mitral valve. Cardiosolutions' pioneering Spacer - Tek TechnologyTM consists of its Percu - Pro SystemTM of measurement, delivery and implantation of its Mitra- SpacerTM and is designed to greatly reduce the degree of mitral regurgitation in patients with either functional or degenerative valve disease. Current treatment methods involve cutting open the chest, separating the ribs at the breastbone and arresting the heart to access the mitral valve, an invasive and expensive surgery necessitating the use of a heart - lung bypass machine. The Percu - Pro SystemTM allows accessing the mitral valve from the patient's femoral vein located in the inner thigh.

"The magic in mitral valve repair will be a safe, effective and percutaneous approach...We believe Cardiosolutions has all of those bases covered." said Steven Tallarida, president of STDMed Inc. Andrea Patisteas, STDMed's Vice President of Sales and Marketing added "Cardiosolutions has established an accomplished, focused team which has the tools to bring this product to market." Cardiosolutions is currently engaged in animal studies of the Percu-Pro SystemTM and Mitra-SpacerTM.

STD Med, Inc., a Stoughton-based manufacturer and developer of medical technologies created Cardiosolutions in 2005. The technology was conceived by the STDMed new product development team and initial product development was funded internally. In addition to Cardiosolutions, other companies that began at STD Med are Angiolink Corporation, Blue Sky Medical S.A., Arthrosurface Incorporated, and Spirus Medical, Inc.

For more on Cardiosolutions Inc. visit http://www.cardiosolutionsinc.com

For more on STD Med Inc. visit http://www.stdmed.com

 ###